PLGA-PEG-Maleimide from PolySciTech used to develop PLGA-PEG-DNA particles for immunomodulation applications

 

DNA-scaffolded nanoparticles can be utilized to modify the behavior of human T-cells. One way to synthesize these is to react PLGA-PEG-Maleimide with thiolated DNA to provide for well controlled chemical synthesis. Researchers at University of California, San Francisco, University of California, Berkeley, Drexel University, and Brown University used PLGA-PEG-Maleimide (AI053) from PolySciTech division of Akina, Inc. (www.polyscitech.com) to create PLGA-PEG-DNA nanoparticles for immune cell modification. This research holds promise to provide for improvements in immunotherapy and other therapeutic applications in the future. Read more: Hadley, Pierce, Yuanzhou Chen, Lariana Cline, Zhiyuan Han, Qizhi Tang, Xiao Huang, and Tejal Desai. "Precise surface functionalization of PLGA particles for human T cell modulation." Protocol Exchange (2023). https://www.researchsquare.com/article/pex-2337/v1

“Abstract: Biofunctionalization of synthetic materials has broad utility in various biomedical applications but was limited by insufficient efficiency and controllability for bioconjugation. Therefore, we developed a new platform of building synthetic DNA-scaffolds on material surfaces to assemble and organize functional cargos, allowing for more precise control over cargo density and ratio. The adaptation of this technology for biomedical applications requires diverse expertise ranging from materials to bioconjugation chemistry to cell biology, and there are many critical checkpoints to ensure the quality of the platform for the expected biological function. In this protocol, we describe the three key fabrication procedures involved: 1) fabrication of polymeric particles engrafted with DNA-scaffolds (3 days), 2) attachment of functional cargos with complementary DNA strands (3-4 days), and 3) surface assembly control and quantification (<1 day). We have also provided additional experimental design considerations for modifying the platform—for example, varying the material composition, size, or cargo types—which may be required for different biological needs. An area of increasing interest is immunomodulation, where immune cells have been recognized for their ability to sense extracellular cues to shape their phenotypic adaptation. We have reported how their modulation can be advanced by this precision biomaterial platform. Here, we exemplify the protocol of primary human T cells activation and identified various parameters that can impact T cell ex vivo manufacturing. This protocol will equip investigators with the necessary fabrication procedures and validation assays to design high-fidelity DNA-scaffolded biomaterials for uses in diverse biomedical applications.”